Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations

Petra Szili, Gábor Draskovits, Tamás Révész, F. Bogár, Dávid Balogh, T. Martinek, Lejla Daruka, Réka Spohn, Bálint Márk Vásárhelyi, Márton Czikkely, Bálint Kintses, Gábor Grézal, Györgyi Ferenc, C. Pál, Ákos Nyerges

Research output: Contribution to journalArticle

Abstract

Multitargeting antibiotics, i.e., single compounds capable of inhibiting two or more bacterial targets, are generally considered to be a promising therapeutic strategy against resistance evolution. The rationale for this theory is that multitargeting antibiotics demand the simultaneous acquisition of multiple mutations at their respective target genes to achieve significant resistance. The theory presumes that individual mutations provide little or no benefit to the bacterial host. Here, we propose that such individual stepping-stone mutations can be prevalent in clinical bacterial isolates, as they provide significant resistance to other antimicrobial agents. To test this possibility, we focused on gepotidacin, an antibiotic candidate that selectively inhibits both bacterial DNA gyrase and topoisomerase IV. In a susceptible organism, Klebsiella pneumoniae, a combination of two specific mutations in these target proteins provide an 2,000-fold reduction in susceptibility, while individually, none of these mutations affect resistance significantly. Alarmingly, strains with decreased susceptibility against gepotidacin are found to be as virulent as the wild-type Klebsiella pneumoniae strain in a murine model. Moreover, numerous pathogenic isolates carry mutations which could promote the evolution of clinically significant reduction of susceptibility against gepotidacin in the future. As might be expected, prolonged exposure to ciprofloxacin, a clinically widely employed gyrase inhibitor, coselected for reduced susceptibility against gepotidacin. We conclude that extensive antibiotic usage could select for mutations that serve as stepping-stones toward resistance against antimicrobial compounds still under development. Our research indicates that even balanced multitargeting antibiotics are prone to resistance evolution.

Original languageEnglish
Article numbere00207-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Anti-Bacterial Agents
Mutation
Klebsiella pneumoniae
DNA Topoisomerase IV
DNA Gyrase
Bacterial DNA
Ciprofloxacin
Anti-Infective Agents
Research
Genes
Proteins
Therapeutics

Keywords

  • Antibiotic resistance
  • Genome engineering
  • Gepotidacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations. / Szili, Petra; Draskovits, Gábor; Révész, Tamás; Bogár, F.; Balogh, Dávid; Martinek, T.; Daruka, Lejla; Spohn, Réka; Vásárhelyi, Bálint Márk; Czikkely, Márton; Kintses, Bálint; Grézal, Gábor; Ferenc, Györgyi; Pál, C.; Nyerges, Ákos.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 9, e00207-19, 01.01.2019.

Research output: Contribution to journalArticle

Szili, P, Draskovits, G, Révész, T, Bogár, F, Balogh, D, Martinek, T, Daruka, L, Spohn, R, Vásárhelyi, BM, Czikkely, M, Kintses, B, Grézal, G, Ferenc, G, Pál, C & Nyerges, Á 2019, 'Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations', Antimicrobial Agents and Chemotherapy, vol. 63, no. 9, e00207-19. https://doi.org/10.1128/AAC.00207-19
Szili, Petra ; Draskovits, Gábor ; Révész, Tamás ; Bogár, F. ; Balogh, Dávid ; Martinek, T. ; Daruka, Lejla ; Spohn, Réka ; Vásárhelyi, Bálint Márk ; Czikkely, Márton ; Kintses, Bálint ; Grézal, Gábor ; Ferenc, Györgyi ; Pál, C. ; Nyerges, Ákos. / Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 9.
@article{4a162671e94046acb460fd5532952e88,
title = "Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations",
abstract = "Multitargeting antibiotics, i.e., single compounds capable of inhibiting two or more bacterial targets, are generally considered to be a promising therapeutic strategy against resistance evolution. The rationale for this theory is that multitargeting antibiotics demand the simultaneous acquisition of multiple mutations at their respective target genes to achieve significant resistance. The theory presumes that individual mutations provide little or no benefit to the bacterial host. Here, we propose that such individual stepping-stone mutations can be prevalent in clinical bacterial isolates, as they provide significant resistance to other antimicrobial agents. To test this possibility, we focused on gepotidacin, an antibiotic candidate that selectively inhibits both bacterial DNA gyrase and topoisomerase IV. In a susceptible organism, Klebsiella pneumoniae, a combination of two specific mutations in these target proteins provide an 2,000-fold reduction in susceptibility, while individually, none of these mutations affect resistance significantly. Alarmingly, strains with decreased susceptibility against gepotidacin are found to be as virulent as the wild-type Klebsiella pneumoniae strain in a murine model. Moreover, numerous pathogenic isolates carry mutations which could promote the evolution of clinically significant reduction of susceptibility against gepotidacin in the future. As might be expected, prolonged exposure to ciprofloxacin, a clinically widely employed gyrase inhibitor, coselected for reduced susceptibility against gepotidacin. We conclude that extensive antibiotic usage could select for mutations that serve as stepping-stones toward resistance against antimicrobial compounds still under development. Our research indicates that even balanced multitargeting antibiotics are prone to resistance evolution.",
keywords = "Antibiotic resistance, Genome engineering, Gepotidacin",
author = "Petra Szili and G{\'a}bor Draskovits and Tam{\'a}s R{\'e}v{\'e}sz and F. Bog{\'a}r and D{\'a}vid Balogh and T. Martinek and Lejla Daruka and R{\'e}ka Spohn and V{\'a}s{\'a}rhelyi, {B{\'a}lint M{\'a}rk} and M{\'a}rton Czikkely and B{\'a}lint Kintses and G{\'a}bor Gr{\'e}zal and Gy{\"o}rgyi Ferenc and C. P{\'a}l and {\'A}kos Nyerges",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.00207-19",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations

AU - Szili, Petra

AU - Draskovits, Gábor

AU - Révész, Tamás

AU - Bogár, F.

AU - Balogh, Dávid

AU - Martinek, T.

AU - Daruka, Lejla

AU - Spohn, Réka

AU - Vásárhelyi, Bálint Márk

AU - Czikkely, Márton

AU - Kintses, Bálint

AU - Grézal, Gábor

AU - Ferenc, Györgyi

AU - Pál, C.

AU - Nyerges, Ákos

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Multitargeting antibiotics, i.e., single compounds capable of inhibiting two or more bacterial targets, are generally considered to be a promising therapeutic strategy against resistance evolution. The rationale for this theory is that multitargeting antibiotics demand the simultaneous acquisition of multiple mutations at their respective target genes to achieve significant resistance. The theory presumes that individual mutations provide little or no benefit to the bacterial host. Here, we propose that such individual stepping-stone mutations can be prevalent in clinical bacterial isolates, as they provide significant resistance to other antimicrobial agents. To test this possibility, we focused on gepotidacin, an antibiotic candidate that selectively inhibits both bacterial DNA gyrase and topoisomerase IV. In a susceptible organism, Klebsiella pneumoniae, a combination of two specific mutations in these target proteins provide an 2,000-fold reduction in susceptibility, while individually, none of these mutations affect resistance significantly. Alarmingly, strains with decreased susceptibility against gepotidacin are found to be as virulent as the wild-type Klebsiella pneumoniae strain in a murine model. Moreover, numerous pathogenic isolates carry mutations which could promote the evolution of clinically significant reduction of susceptibility against gepotidacin in the future. As might be expected, prolonged exposure to ciprofloxacin, a clinically widely employed gyrase inhibitor, coselected for reduced susceptibility against gepotidacin. We conclude that extensive antibiotic usage could select for mutations that serve as stepping-stones toward resistance against antimicrobial compounds still under development. Our research indicates that even balanced multitargeting antibiotics are prone to resistance evolution.

AB - Multitargeting antibiotics, i.e., single compounds capable of inhibiting two or more bacterial targets, are generally considered to be a promising therapeutic strategy against resistance evolution. The rationale for this theory is that multitargeting antibiotics demand the simultaneous acquisition of multiple mutations at their respective target genes to achieve significant resistance. The theory presumes that individual mutations provide little or no benefit to the bacterial host. Here, we propose that such individual stepping-stone mutations can be prevalent in clinical bacterial isolates, as they provide significant resistance to other antimicrobial agents. To test this possibility, we focused on gepotidacin, an antibiotic candidate that selectively inhibits both bacterial DNA gyrase and topoisomerase IV. In a susceptible organism, Klebsiella pneumoniae, a combination of two specific mutations in these target proteins provide an 2,000-fold reduction in susceptibility, while individually, none of these mutations affect resistance significantly. Alarmingly, strains with decreased susceptibility against gepotidacin are found to be as virulent as the wild-type Klebsiella pneumoniae strain in a murine model. Moreover, numerous pathogenic isolates carry mutations which could promote the evolution of clinically significant reduction of susceptibility against gepotidacin in the future. As might be expected, prolonged exposure to ciprofloxacin, a clinically widely employed gyrase inhibitor, coselected for reduced susceptibility against gepotidacin. We conclude that extensive antibiotic usage could select for mutations that serve as stepping-stones toward resistance against antimicrobial compounds still under development. Our research indicates that even balanced multitargeting antibiotics are prone to resistance evolution.

KW - Antibiotic resistance

KW - Genome engineering

KW - Gepotidacin

UR - http://www.scopus.com/inward/record.url?scp=85071229114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071229114&partnerID=8YFLogxK

U2 - 10.1128/AAC.00207-19

DO - 10.1128/AAC.00207-19

M3 - Article

C2 - 31235632

AN - SCOPUS:85071229114

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

M1 - e00207-19

ER -